Phase II trial of sorafenib in advanced thyroid cancer.
By V. Gupta-Abramson, Andrea B. Troxel, A. Nellore, Kanchan Puttaswamy, M. Redlinger, K. Ransone, S. Mandel, K. Flaherty, L. Loevner, P. O'dwyer and 1 more. Journal of Clinical Oncology, 2008
698 citations recorded by the source corpus.
Subfields: Cancer Research, Endocrinology, Diabetes and Metabolism
View Paper: https://www.semanticscholar.org/paper/dd79f37dafae5c35c2b2902135695c4f54dc70d3
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
Citations in the corpus
- American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer (2012, background): “Sorafenib, a multitargeted tyrosine kinase inhibitor that weakly inhibits the BRAF gene product and more potently inhibits angiogenesis via inhibition of VEGF-Rs bAU6 has also been assessed in a small number of ATC patients in two recent phase II clinical trials, with no RECIST responses seen in six”